Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5) announced today that its shareholders approved all motions on the agenda for the ordinary part of the Annual General Meeting (AGM) 2026 held on April 23, 2026. The approvals included the election of George Garibaldi and Paolo Zocchi as new, independent, and non-executive Board members.
The motions on the agenda for the extraordinary part of the meeting were not put to a vote because the required quorum was not reached. Newron did not specify the nature of the extraordinary motions or the quorum requirements.
Chris Martin, Chairman of the Board of Directors of Newron, expressed gratitude to shareholders for their trust and welcomed the newly elected board members. He also thanked Patrick Langlois and Luca Benatti, who stepped down from the Board after their long-standing service, for their support.
Newron Pharmaceuticals is a biopharmaceutical company focused on developing therapies for central and peripheral nervous system diseases. Its lead compound, evenamide, is a first-in-class glutamate modulator being developed for treatment-resistant schizophrenia (TRS) and poorly responding schizophrenia patients, currently in the global pivotal ENIGMA-TRS Phase III program. The company has partnerships with EA Pharma (Eisai) for Japan and other Asian territories, and Myung In Pharm for South Korea. Its marketed product, Xadago®/safinamide, is approved for Parkinson's disease in multiple regions and commercialized by partners Zambon, Supernus Pharmaceuticals, and Meiji Seika.
For more information, visit www.newron.com.
